249 related articles for article (PubMed ID: 36690898)
1. Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein.
Zhang S; Zhu R; Pan B; Xu H; Olufemi MF; Gathagan RJ; Li Y; Zhang L; Zhang J; Xiang W; Kagan EM; Cao X; Yuan C; Kim SJ; Williams CK; Magaki S; Vinters HV; Lashuel HA; Garcia BA; James Petersson E; Trojanowski JQ; Lee VM; Peng C
Nat Neurosci; 2023 Feb; 26(2):213-225. PubMed ID: 36690898
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
Chen H; Zhao YF; Chen YX; Li YM
ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.
Schmid AW; Fauvet B; Moniatte M; Lashuel HA
Mol Cell Proteomics; 2013 Dec; 12(12):3543-58. PubMed ID: 23966418
[TBL] [Abstract][Full Text] [Related]
4. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications.
Vicente Miranda H; Xiang W; de Oliveira RM; Simões T; Pimentel J; Klucken J; Penque D; Outeiro TF
J Neurochem; 2013 Sep; 126(5):673-84. PubMed ID: 23534813
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders.
Lu Y; Prudent M; Fauvet B; Lashuel HA; Girault HH
ACS Chem Neurosci; 2011 Nov; 2(11):667-75. PubMed ID: 22860160
[TBL] [Abstract][Full Text] [Related]
6. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.
He S; Wang F; Yung KKL; Zhang S; Qu S
ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791
[TBL] [Abstract][Full Text] [Related]
7. Implications of In Vitro Multi-Serine Phosphorylation of Alpha-Synuclein in Aggregation and Cytotoxicity.
Chaturvedi M; Raj R; Yadav SK; Srivastava T; Devi S; Dharmadana D; Valéry C; Sharma SK; Kumar D; Priya S
ACS Chem Neurosci; 2023 Sep; 14(17):3103-3112. PubMed ID: 37562012
[TBL] [Abstract][Full Text] [Related]
8. An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels.
Serratos IN; Hernández-Pérez E; Campos C; Aschner M; Santamaría A
Mol Neurobiol; 2022 Jan; 59(1):620-642. PubMed ID: 34750787
[TBL] [Abstract][Full Text] [Related]
9. Semisynthesis and Enzymatic Preparation of Post-translationally Modified α-Synuclein.
Fauvet B; Lashuel HA
Methods Mol Biol; 2016; 1345():3-20. PubMed ID: 26453202
[TBL] [Abstract][Full Text] [Related]
10. Preserved proteinase K-resistant core after amplification of alpha-synuclein aggregates: Implication to disease-related structural study.
Yoshinaga S; Yamanaka T; Miyazaki H; Okuzumi A; Hiyama A; Murayama S; Nukina N
Biochem Biophys Res Commun; 2020 Feb; 522(3):655-661. PubMed ID: 31785806
[TBL] [Abstract][Full Text] [Related]
11. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease.
Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y
BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294
[TBL] [Abstract][Full Text] [Related]
12. Transmission of α-synuclein seeds in neurodegenerative disease: recent developments.
Karpowicz RJ; Trojanowski JQ; Lee VM
Lab Invest; 2019 Jul; 99(7):971-981. PubMed ID: 30760864
[TBL] [Abstract][Full Text] [Related]
13. Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.
Duce JA; Wong BX; Durham H; Devedjian JC; Smith DP; Devos D
Mol Neurodegener; 2017 Jun; 12(1):45. PubMed ID: 28592304
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Braithwaite SP; Stock JB; Mouradian MM
Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
[TBL] [Abstract][Full Text] [Related]
15. The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson's Disease.
Battis K; Xiang W; Winkler J
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686080
[TBL] [Abstract][Full Text] [Related]
16. Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?
Brembati V; Faustini G; Longhena F; Bellucci A
Front Mol Neurosci; 2023; 16():1197853. PubMed ID: 37305556
[TBL] [Abstract][Full Text] [Related]
17. The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates.
Neupane S; De Cecco E; Aguzzi A
J Mol Biol; 2023 Jun; 435(12):167930. PubMed ID: 36566800
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein arginylation in the human brain.
Zhao J; Pan B; Fina M; Huang Y; Shimogawa M; Luk KC; Rhoades E; Petersson EJ; Dong DW; Kashina A
Transl Neurodegener; 2022 Apr; 11(1):20. PubMed ID: 35395956
[TBL] [Abstract][Full Text] [Related]
19. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
Miao Y; Meng H
Cell Commun Signal; 2024 Jan; 22(1):31. PubMed ID: 38216911
[TBL] [Abstract][Full Text] [Related]
20. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
